Angle gained its first FDA approval relating to metastatic breast cancer on 25 May 2022 after a process that took nearly 6.5 years. Within days it announced a significant collaboration with a US Urology company re prostate cancer. Results of an ovarian cancer trial are expected soon. Work is already being undertaken with Abbott and likely with Astra Zeneca. Apparently there are ongoing discussions with several other pharmas.
I expect there will be many news items worthy of discussion by shareholders which are not particularly suited to the SCVR so I have opted to start this thread as an alternative platform. By way of starting I’ve copied below a posting I made belatedly on SCVR last Friday (3/6) re an article in the FT.
Having watched a very interesting programme on cancer treatment broadcast on the Beeb yesterday evening the following article was in the FT today. [I cribbed from the post by asdb9 another BB].
Pharmaceutical companies are lining up to use a pioneering cancer test developed by UK start-up Angle after it received a first-of-its-kind US regulatory clearance. Angle’s liquid biopsy test captures live cancer cells in the blood that clinicians can use to personalise treatment by understanding the mutations and gene expression in each patient’s cancer. Shares in the London-listed company jumped almost 60 per cent on the day the Food and Drug Administration gave the test clearance for use in metastatic breast cancer. The Surrey-based start-up already works with US drugmaker Abbott to use its test to identify patients who will respond to its treatment Herceptin. It is working on a trial in ovarian cancer and this week signed a deal with Philadelphia-based MidLantic Urology to study its test in prostate cancer. Andrew Newland, chief executive, said other companies had approached Angle since the clearance last week because the test enables them to follow their progress as the drug tackles tumours. Ultimately, it hopes they will develop diagnostics as companions to each drug. ‘Our vision is that we’re going to transform the way that cancer is diagnosed and treated for every cancer type worldwide,’ he said.’So we either have to be a very, very large company, or as we’re currently planning, we have to have many deals with very large companies to achieve that’ He said Angle wants to help clinicians who are ‘flying blind’, trying to work out which treatments a patient will respond to.…
